VISHEE(SH:688580)2024-04-25 09:20Financial Performance - The company reported a net profit attributable to shareholders of RMB 136,258,629.02 for the year 2023, with a total distributable profit of RMB 416,851,513.83[7]. - A cash dividend of RMB 1.5032 per share (including tax) is proposed, with an expected total cash dividend payout of RMB 102,194,339.48, representing 83.49% of the net profit for the year[9]. - The company reported a revenue of RMB 1.2 billion for the fiscal year 2023, representing a year-on-year growth of 15%[18]. - The company's operating revenue for 2023 reached ¥462,223,134.18, representing a year-on-year increase of 43.72% compared to ¥321,621,418.85 in 2022[29]. - Net profit attributable to shareholders for 2023 was ¥136,258,629.02, up 45.22% from ¥93,825,897.99 in the previous year[30]. - The net profit after deducting non-recurring gains and losses was ¥121,726,312.07, reflecting a significant increase of 58.93% compared to ¥76,590,650.79 in 2022[30]. - The gross margin for the year was reported at 45%, an improvement from 42% in the previous year[18]. - The company achieved total operating revenue of CNY 46,222.31 million in the reporting period, representing a year-on-year increase of 43.72%[39]. - The company reported a net cash flow from operating activities of CNY 62,656.86 million in the fourth quarter, indicating strong operational efficiency[33]. Shareholder Actions - The company plans to increase its total share capital from 68,623,867 shares to 95,817,677 shares through a capital reserve transfer of 27,193,810 shares[10]. - The proposed profit distribution and capital reserve transfer plan has been approved by the board and will be submitted for shareholder approval[11]. - The company implemented a stock incentive plan that resulted in a post-tax share-based payment expense of ¥16,704,900, which impacted the net profit[30]. - The company plans to implement a stock incentive plan for 2023, which was discussed in the shareholders' meeting[193]. Risk Management - The company has outlined various risks and countermeasures in its annual report, emphasizing the importance of risk management[5]. - The board of directors and management have confirmed the accuracy and completeness of the financial report, ensuring no significant omissions or misleading statements[5]. - The company emphasizes that forward-looking statements regarding future plans and strategies do not constitute a commitment to investors, highlighting the associated investment risks[12]. Market Expansion and Product Development - User data indicates an increase in active users by 20% compared to the previous year, reaching a total of 500,000 users[18]. - The company projects a revenue growth of 10% for the next fiscal year, targeting RMB 1.32 billion[18]. - New product development includes the launch of a next-generation rehabilitation robot, expected to enhance patient recovery rates by 30%[18]. - The company has expanded its market presence by entering three new provinces, aiming to increase market share by 5%[18]. - A strategic acquisition of a competitor was completed, valued at RMB 300 million, expected to enhance product offerings and market reach[18]. - The company is investing RMB 50 million in R&D for innovative rehabilitation technologies over the next two years[18]. - The company aims to continue expanding its market presence and developing new technologies to enhance its product offerings[22]. Research and Development - The R&D expenditure as a percentage of operating revenue was 16.97%, a decrease of 2.10 percentage points from 19.07% in 2022[31]. - The total R&D investment for the year reached ¥78,432,505.46, representing a 27.86% increase compared to the previous year[116]. - The company has established six major technology platforms, including magnetic stimulation, electrical stimulation, electrophysiology, robotics, laser, and radiofrequency, to support its product lines[51]. - The company is committed to increasing R&D investment in key projects and enhancing its intellectual property portfolio to ensure sustainable long-term growth[40]. - The company has obtained 36 patents, including 16 invention patents, 9 utility model patents, and 11 design patents, with 47 new authorized patents during the reporting period[42]. Operational Efficiency - The company plans to enhance its digital platform, aiming for a 25% increase in user engagement through improved features[18]. - The company has set a target to reduce operational costs by 8% in the upcoming year through efficiency improvements[18]. - The company is focusing on building a comprehensive rehabilitation device ecosystem, covering pelvic, neurological, mental, and physical rehabilitation[50]. - The company aims to improve operational efficiency and clinical evaluation through advanced data analysis techniques[122]. Customer Satisfaction and Service - Customer satisfaction ratings increased to 90%, reflecting improvements in service and product quality[199]. - The company emphasizes customer satisfaction and has developed a comprehensive after-sales service system, enhancing customer experience and service quality[135]. - The company is focused on digital operations and efficient after-sales service, utilizing CRM and electronic data monitoring systems to improve management efficiency[135]. Governance and Compliance - The company aims to enhance its governance and operational management through various committees established under the board[189]. - The company held 1 shareholders' meeting during the reporting period, complying with relevant laws and regulations[189]. - A total of 6 board meetings were convened, with independent directors attending and providing independent opinions[190]. - The supervisory board held 5 meetings, ensuring compliance with legal and regulatory requirements[190].